Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:20 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma
NCT05711628 · National Cancer Institute (NCI) · PHASE3 · withdrawn · last registry update 2024-03-20 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Other - Protocol moved to Withdrawn” | – | Registry record, National Cancer Institute (NCI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TUBB4B within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-03-03Phase 3 first posted: Novartis Pharmaceuticals, AAA817 + ARPI (NCT06855277)
- 2025-02-11Phase 3 first posted: Children's Oncology Group, Cyclophosphamide + Doxorubicin Hydrochloride (NCT06820957)
- 2025-01-08Phase 3 first posted: Institute of Hematology & Blood Diseases Hospital, China, Blinatumomab (Group A) + Venetoclax (nonRand Group) (NCT06764238)
- 2024-12-05Phase 3 first posted: Merck Sharp & Dohme LLC, Zilovertamab vedotin + Rituximab (NCT06717347)
- 2024-11-08Results posted on the registry: Massachusetts General Hospital, Eribulin (NCT03331250)
- 2024-10-18Phase 3 first posted: Children's Oncology Group, Cyclophosphamide + Dactinomycin (NCT06647953)
- 2024-10-09Phase 3 first posted: Alliance for Clinical Trials in Oncology, Cisplatin + Carboplatin (NCT06632327)
- 2024-10-01Results posted on the registry: National Cancer Institute (NCI), Cyclophosphamide + Dactinomycin (NCT02567435)
- 2024-09-24Results posted on the registry: National Cancer Institute (NCI), Blinatumomab + Cyclophosphamide (NCT02003222)
- 2024-08-26Results posted on the registry: Hoffmann-La Roche, Alectnib + Cisplatin (NCT03456076)
- 2024-08-26Results posted on the registry: City of Hope Medical Center, Carboplatin + Etoposide (NCT04665765)
- 2024-08-21Phase 3 first posted: AstraZeneca, Datopotamab Deruxtecan + Rilvegostomig (NCT06564844)
- 2024-08-12Phase 3 first posted: AstraZeneca, Surovatamig + R-CHOP (NCT06549595)
- 2024-06-14Phase 3 first posted: Merck Sharp & Dohme LLC, Sacituzumab Tirumotecan + Pemetrexed (NCT06459180)
- 2024-05-06Phase 3 first posted: Children's Oncology Group, Carboplatin + Cyclophosphamide (NCT06401330)
- 2024-04-24Phase 3 first posted: Sichuan Baili Pharmaceutical Co., Ltd., BL-B01D1 + Eribulin (NCT06382142)
- 2024-04-18Results posted on the registry: Adrienne G. Waks, Vinorelbine + Trastuzumab (NCT03414658)
- 2024-04-10Phase 3 first posted: Celgene, Golcadomide + Placebo (NCT06356129)
- 2024-04-03Phase 3 first posted: Sichuan Baili Pharmaceutical Co., Ltd., BL-B01D1 + Eribulin (NCT06343948)
- 2024-02-28Phase 3 first posted: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., SKB264 + Paclitaxel (NCT06279364)
- 2024-02-28Phase 3 first posted: The Lymphoma Academic Research Organisation, Mosunetuzumab + Lenalidomide (NCT06284122)
- 2024-02-16Phase 3 first posted: Intensity Therapeutics, Inc., INT230-6 + Eribulin (NCT06263231)
- 2024-01-23Phase 3 first posted: Stichting Hemato-Oncologie voor Volwassenen Nederland, Dexrazoxane + Rituximab (NCT06220032)
- 2024-01-05Phase 3 first posted: Genmab, Epcoritamab + Prednisone (NCT06191744)
- 2024-01-03Phase 3 first posted: National Research Center for Hematology, Russia, Cyclophosphamide + Doxorubicin Hydrochloride (NCT06188676)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision